Asensus Surgical Announces the Appointment of Two New Board Members
26 Julho 2021 - 7:55AM
Business Wire
Asensus Surgical, Inc. (NYSE American: ASXC), a medical device
company that is digitizing the interface between the surgeon and
the patient to pioneer a new era of Performance-Guided Surgery™,
today announced the expansion of its Board of Directors, appointing
two new board members, Elizabeth Kwo, MD and Kevin Hobert,
effective immediately.
“We are delighted to welcome two accomplished industry veterans
to our Board of Directors, each of whom bring highly relevant and
unique skills to the organization that complement our current
leadership team in an impactful way,” said Paul LaViolette,
Chairman of the Board of Asensus Surgical. “Liz has a tremendous
track record of bringing innovative healthcare technology to the
market, and has a highly specialized expertise in leveraging
predictive analytics and big data to improve patient outcomes
through digital solutions, making her a perfect fit as we seek to
revolutionize digital surgery. Kevin has extensive experience
leading global technology businesses, and importantly was an
integral part in the early development of innovative digital
imaging technology that leveraged AI and proprietary algorithms. We
look forward to tapping into their combined talents as we continue
to work to drive the widespread commercial adoption of Senhance®
Surgical System on a global scale.”
Elizabeth Kwo, MD specializes in healthcare technology product
development and medical management. She currently serves as the
Deputy Chief Clinical Officer at Anthem, Inc., a position she has
held since December 2020. In that role, she is responsible for
modernizing care management with predictive analytics and
integrating clinical data to create an improved automated patient
and provider experience that drives down total medical costs and
increases access to care. Dr. Kwo served as Staff Vice President,
Clinical Analytics and Products for Anthem, Inc. from June to
November 2020 and as Medical Director from November 2019 to May
2020. Prior to Anthem, Dr. Kwo cofounded and served as the Chief
Executive Officer of the telemedicine company InfiniteMD from 2015
to 2019. She previously worked in management roles at Medtronic,
Inc., American Well Corporation, and founded multiple
venture-backed companies in healthcare while continuing her
academic appointment at Harvard Medical School as a Faculty
Lecturer, a position she continues to hold. Dr. Kwo earned a BA, in
Human Biology from Stanford University, a MD from Harvard Medical
School, an MBA from Harvard Business School, and an MPH from
Harvard T.H. Chan School of Public Health. She completed her
residency in Preventive Care at Harvard Preventive Care and is
Board Certified in Preventive Care and Occupational Medicine. She
currently serves on the Board of Directors of Flexion Therapeutics,
Inc., a biopharmaceutical company. From 2004 to 2005, she served as
a Fullbright Fellow in Taiwan.
“Asensus has made remarkable progress expanding their portfolio
and bringing transformative technology to surgeons,” said Dr. Kwo.
“The opportunity to address underserved areas of surgery around the
world with this unique approach excites me, and I am pleased to be
working with such a dedicated leadership team who believe in the
vision of Performance-Guided Surgery.”
Kevin Hobert has decades of medical technology leadership
experience as well as expertise in transaction advisory and
acquisition integration. Mr. Hobert currently serves as the
principal of Beaver Lake Advisors LLC, a consulting firm formed in
September 2018 to provide industry and transaction advisory
services to private equity funds. From May 2007 to August 2018, Mr.
Hobert served as the Chief Executive Officer of Carestream Health,
Inc., a worldwide provider of medical imaging systems, X-ray
imaging systems for non-destructive testing and precision contract
coating services for a wide range of industrial, medical,
electronic and other applications. Prior to May 2007, Mr. Hobert
served in a variety of management positions for Kodak Health Group,
a division of Eastman Kodak Company, and GE Medical Systems, Inc.
(now GE Healthcare, Inc.). Mr. Hobert earned a BS, Physics from the
University of Wisconsin-Milwaukee.
“I am thrilled to join the Asensus Surgical Board of Directors
at such an important time for the company,” said Mr. Hobert. “The
Senhance Surgical System is a compelling and powerful tool to
improve patient outcomes. I look forward to using my past
experience to help Asensus take advantage of the massive
opportunity that exists for Senhance.”
About Asensus Surgical, Inc.
Asensus Surgical, Inc. is digitizing the interface between the
surgeon and patient to pioneer a new era of Performance-Guided
Surgery by unlocking clinical intelligence for surgeons to enable
consistently superior outcomes and a new standard of surgery. This
builds upon the foundation of Digital Laparoscopy with the Senhance
Surgical System powered by the Intelligent Surgical Unit™ (ISU™) to
increase surgeon control and reduce surgical variability. With the
addition of machine vision, augmented intelligence, and deep
learning capabilities throughout the surgical experience, we intend
to holistically address the current clinical, cognitive and
economic shortcomings that drive surgical outcomes and value-based
healthcare. Learn more about Performance-Guided Surgery and Digital
Laparoscopy with the Senhance Surgical System here:
www.senhance.com. Now available for sale in the US, EU, Japan,
Russia, and select other countries. For a complete list of
indications for use, visit: www.senhance.com/indications. For more
information, visit www.asensus.com.
Forward-Looking Statements
This press release includes statements regarding additions to
our Board of Directors which constitute "forward-looking
statements" within the meaning of Section 27A of the Securities Act
of 1933 and Section 21E of the Securities Exchange Act of 1934, and
are intended to qualify for the safe harbor from liability
established by the Private Securities Litigation Reform Act of
1995. Such statements are subject to risks and uncertainties that
are often difficult to predict, are beyond our control and which
may cause results to differ materially from expectations and
include whether Dr. Kwo will be a perfect fit as a Board member as
we seek to revolutionize surgery and whether the two new Board
members’ combined talents will help the Company’s efforts to drive
the widespread commercial adoption of the Senhance Surgical System
on a global scale. For a discussion of the risks and uncertainties
associated with Asensus Surgical's business, please review our
filings with the Securities and Exchange Commission (SEC),
including our Annual Report on Form 10-K for the year ended
December 31, 2020, which we filed with the SEC on March 11, 2021.
You are cautioned not to place undue reliance on these
forward-looking statements, which are based on our expectations as
of the date of this press release and speak only as of the
origination date of this press release. We undertake no obligation
to publicly update or revise any forward-looking statement, whether
as a result of new information, future events or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210726005181/en/
INVESTOR CONTACT: Mark Klausner or Mike Vallie,
443-213-0499 invest@asensus.com or MEDIA CONTACT: Kristin
Schaeffer CG Life kschaeffer@cglife.com
Asensus Surgical, Inc. (NYSE:ASXC)
Gráfico Histórico do Ativo
De Fev 2025 até Mar 2025
Asensus Surgical, Inc. (NYSE:ASXC)
Gráfico Histórico do Ativo
De Mar 2024 até Mar 2025